Ann: June 2019 Appendix 4C - Quarterly, page-70

Curious, how are they testing their phase 1B for AML with PXT-200? What read-outs are they looking at?

Think the story of personalized medicine for ATK pathways is nice. ROH and RAS mutations are common enough in the cancer lines they're targetting. They should be able to hit significant results if they have shown that PTX-200 can target such mutations and consequently reduce proliferation, apoptosis.... ATK pathways are well studied. MTOR activation also in cancer lines.

Phase 1b results are my major interest, gets exponentially more difficult to get a bio-play across the line after that. Especially in the oncology end. My thoughts.

Seems like there is a bit of time before results are due, mind you... late september / early october? right?

Cheers,
M